metoprolol has been researched along with Cardiotoxicity in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier." | 9.30 | The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients. ( Charpidou, A; Georgakopoulos, P; Karavidas, A; Kouvela, M; Kyriakidis, M; Mamalis, N; Perpinia, A; Zimeras, S, 2019) |
| "Our objectives were to validate a murine model of chronic cardiotoxicity induced by Doxorubicin (Dox) and Trastuzumab (Trast) and to test the potential cardio-protective effect of metoprolol." | 8.02 | Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol. ( Azibani, F; Cohen-Solal, A; Launay, JM; Nicol, M; Polidano, E; Sadoune, M; Samuel, JL, 2021) |
| " The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier." | 5.30 | The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients. ( Charpidou, A; Georgakopoulos, P; Karavidas, A; Kouvela, M; Kyriakidis, M; Mamalis, N; Perpinia, A; Zimeras, S, 2019) |
| " The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines." | 5.24 | Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. ( Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Norseth, J; Omland, T; Ree, AH; Røsjø, H; Steine, K, 2017) |
| "Our objectives were to validate a murine model of chronic cardiotoxicity induced by Doxorubicin (Dox) and Trastuzumab (Trast) and to test the potential cardio-protective effect of metoprolol." | 4.02 | Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol. ( Azibani, F; Cohen-Solal, A; Launay, JM; Nicol, M; Polidano, E; Sadoune, M; Samuel, JL, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Georgakopoulos, P | 1 |
| Kyriakidis, M | 1 |
| Perpinia, A | 1 |
| Karavidas, A | 1 |
| Zimeras, S | 1 |
| Mamalis, N | 1 |
| Kouvela, M | 1 |
| Charpidou, A | 1 |
| Nicol, M | 1 |
| Sadoune, M | 1 |
| Polidano, E | 1 |
| Launay, JM | 1 |
| Samuel, JL | 1 |
| Azibani, F | 1 |
| Cohen-Solal, A | 1 |
| Gulati, G | 1 |
| Heck, SL | 1 |
| Røsjø, H | 1 |
| Ree, AH | 1 |
| Hoffmann, P | 1 |
| Hagve, TA | 1 |
| Norseth, J | 1 |
| Gravdehaug, B | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Omland, T | 1 |
| Khwaja, S | 1 |
| Mahmood, T | 1 |
| Siddiqui, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol[NCT01434134] | Phase 2 | 130 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for metoprolol and Cardiotoxicity
| Article | Year |
|---|---|
The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients.
Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Doxorubicin; Echocardiograp | 2019 |
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antibiotics, | 2017 |
2 other studies available for metoprolol and Cardiotoxicity
| Article | Year |
|---|---|
Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol.
Topics: Animals; Cardiotoxicity; Doxorubicin; Male; Metoprolol; Mice; Mice, Inbred C57BL; Stroke Volume; Tra | 2021 |
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarker | 2016 |